Skp2 |
Multiple myeloma |
Compound A (CpdA) |
|
Interferes Skp2-Skp1 interaction and stabilizes p27 |
(49) |
|
Prostate cancer |
SMIP004 |
|
Downregulates Skp2 |
(51) |
|
Metastatic melanoma, prostate, breast, ovarian, lung cancer |
C1, C2, C16, C20 |
|
Binds to a pocket formed by Skp2 and Cks1 to block substrate binding |
(52) |
|
Cancer, general |
Compound #25 |
|
Binds to Skp2 and prevents Skp2-Skp1 interaction |
(47) |
|
Breast, prostate cancer |
Curcumin |
|
Natural agents, inhibit Skp2 expression |
(146–148) |
|
|
Quercetin |
|
|
|
|
|
Lycopene |
|
|
|
|
|
silibinin |
|
|
|
|
|
EGCG |
|
|
|
|
|
Vitamin D |
|
|
|
κ-TrCP |
Inflammation |
GS143 |
|
Disrupts interaction between phospho-IκBκκ and κ-TrCP and suppress IκBκ ubiquitylation |
(65) |
|
Cancer, general |
Erioflorin |
|
Inhibits the interaction between κ-TrCP and tumor suppressor Pdcd4 |
(71) |
Fbxw7 |
Pancreatic cancer |
SINE KPT-185 |
|
Inhibits nuclear export of Fbxw7, enhances nuclear retention of Fbxw7 and degrades Notch1 |
(149) |
|
Leukemia, lymphoma |
Oridonin |
|
Increases Fbxw7 expression, activates GSK3 and facilitates c-Myc turnover |
(150) |
|
|
Genistein |
|
Inhibits miR-223 expression and elevates its target Fbxw7 expression |
(87) |
Fbxl2 |
Inflammation |
BC-1215 |
|
Inhibits the Fbxo3 and Fbxl2 binding |
(28) |
|
|
BC-1258 |
|
Inhibits binding between Fbxo3 and Fbxl2, stabilizes Fbxl2 and promotes Aurora B degradation |
(103) |
Fbxl3 |
circadian-related disorders (sleep disorder, cancer, cardiovascular and metabolic diseases |
KL001 |
|
Competes for binding in the FAD pocket of CRYs and prevents Fbxl3 binding |
(151,152) |